Global Cancer Cell Market to Surpass US$ 14,803.5 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE–(BUSINESS WIRE)–#Cancer–According to Coherent Market Insights, the global cancer cell market is estimated to be valued at US$ 8,525.5 million in 2020 and is expected to exhibit a CAGR of 8.20 % during the forecast period (2020-2027).

Key Trends and Analysis of the Global Cancer Cell Market:

Key companies focusing on inorganic strategies such as collaborations to develop treatment for various cancers such lung, head, and neck cancer are expected to propel growth of the global cancer cell market during the forecast period. For instance, in November 2020, QIAGEN N.V, announced a strategic collaboration with BioNTech SE. The collaboration aims to develop and commercialize a tissue-based companion diagnostic, which can be used in combination with investigational cancer treatment BNT113, which identifies patients with squamous cell carcinoma of the head and neck (SCCHN) that are caused by specific infections by human papilloma virus (HPV).

Among regions, North America is expected to hold dominant position in the global cancer cell market during the forecast period, owing to research institutes and academic institutes focusing on research and development for the treatment of cancer. For instance, on December 03 2020, Dana-Farber Cancer Institute, announced that CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) exhibits ability to treat cancer cells to undetectable levels in around 80% of patients with advanced non-Hodgkin lymphoma (NHL), and is currently under phase 2 clinical trial.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4338

Key Market Takeaways:

The global cancer cell market is expected to exhibit a CAGR of 8.20 % during the forecast period, as key companies are focusing on research and development for the treatment of cancer such as lung cancer, breast cancers and others. For instance, in October 2020, Novartis announced that they received marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe (“FBRI”) to manufacture and supply commercial Kymriah (tisagenlecleucel) for patients suffering from cancer in Japan. This approval makes FBRI the first and only approved commercial manufacturing site for CAR-T cell therapy in Asia Pacific.

Competitive Landscape:

Key players operating in the global cancer cell market include Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics, Kite Pharma, Cellectis, Celyad Oncology, Crescendo Biologics Limited, GammaDelta Therapeutics Ltd., Bio-Rad Laboratories Inc, QIAGEN Inc, Thermo Fisher Scientific, Merck Millipore, Siemens Healthineers AG, and GE Healthcare.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4338

Market Segmentation:

• Global Cancer Cell Market, By Cancer Cell Type:
  • Carcinomas
  • Sarcomas
  • Leukemia
  • Others
• Global Cancer Cell Market, By Application:
  • Chemotherapy.
  • Radiation Therapy
  • Immunotherapy
  • Hormone Therapy
  • Targeted Drug Therapy
  • Others
• Global Cancer Cell Market, By End User :
  • Hospitals & Clinics
  • Specialty Clinics
  • Diagnostic Laboratories
• Global Cancer Cell Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa

Related Market Intelligence Reports:

Cancer Biologics Market, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), by Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, and Others), by Distribution Channel (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/ongoing-insight/cancer-biologics-market-4145

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter